Targovax ASA: Fourth quarter 2019 results
Oslo, Norway, 11 March 2020 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2019 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET (details below). HIGHLIGHTS FOR THE FOURTH QUARTER 2019 · In October, Targovax was selected for oral presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting. The presentation was given by Dr. Alexander Shoushtari, Principal Investigator of ONCOS-102 trial in